For research use only. Not for therapeutic Use.
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1].
Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG[1].
Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice[1].
| Catalog Number | I043206 |
| CAS Number | 2451856-97-4 |
| Purity | ≥95% |
| Reference | [1]. Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021. |
